|
|
|
|
|
Information
|
|
|
What's New |
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis |
© 2013 Direct-MS. All Rights Reserved.
|
|
|
|
|
|
|
Information
|
|
|
What's New |
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis |